BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25640025)

  • 1. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival.
    Yang JZ; Lian WG; Sun LX; Qi DW; Ding Y; Zhang XH
    Pathol Res Pract; 2016 Mar; 212(3):210-6. PubMed ID: 26774288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
    Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
    Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
    Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
    Tucker SM; Zaihra T
    Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
    Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
    Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
    [No Abstract]   [Full Text] [Related]  

  • 11. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis.
    Yang JZ; Wu XD; Meng JB; Zhang JQ; Sun LX
    Pathol Res Pract; 2018 Oct; 214(10):1694-1699. PubMed ID: 30196985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics of extramedullary manifestations in multiple myeloma.
    Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
    Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
    Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of TP53 mutation in myeloma.
    Chng WJ; Price-Troska T; Gonzalez-Paz N; Van Wier S; Jacobus S; Blood E; Henderson K; Oken M; Van Ness B; Greipp P; Rajkumar SV; Fonseca R
    Leukemia; 2007 Mar; 21(3):582-4. PubMed ID: 17215851
    [No Abstract]   [Full Text] [Related]  

  • 18. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
    Chang H; Qi C; Yi QL; Reece D; Stewart AK
    Blood; 2005 Jan; 105(1):358-60. PubMed ID: 15339849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
    Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.